Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: GlobeNewswire
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financial results and business highlights for the year ended December 31, 2025. Net income for the year ended December 31, 2025 was $1.23 Billion and diluted earnings per ordinary share (EPS) was $25.48, driven by appreciation in the valuation of the Company’s treasury and treasury-related derivative assets. Enlivex is a quality longevity Company powered by a Prediction Markets Treasury, reflecting the Company’s dual strategy spanning quality longevity therapeutics and prediction markets infrastructure. Full Year 2025 Financial Summary (audited balance sheet data as of December 31, 2025) Net income: $1.23 Billion Diluted earnings per share (EPS): $25.48 Total treasury and treasury-related derivative assets: $2.31 Billion Shareholders’ equity: $1.93 Billion Cash, cash equiv
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single PromptGlobeNewswire
- Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase ProgramGlobeNewswire
- Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisGlobeNewswire
- Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency ExchangeGlobeNewswire
- Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency ExchangeGlobeNewswire
ENLV
Analyst Actions
- 1/12/26 - HC Wainwright
ENLV
Sec Filings
- 3/26/26 - Form 6-K
- 3/25/26 - Form 20-F
- 3/25/26 - Form 6-K
- ENLV's page on the SEC website